Phase II trial of saracatinib (AZD0530), an oral src-inhibitor for the treatment of patients with hormone receptor negative metastatic breast cancer

BACKGROUND: Src activation is associated with cell migration, proliferation and metastasis. Saracatinib is an oral, tyrosine kinase inhibitor (TKI) selective for Src. We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)- and p...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Gucalp, Ayca, Sparano, Joseph A., Caravelli, James, Santamauro, Jean, Patil, Sujata, Abbruzzi, Alyson, Pellegrino, Christine, Bromberg, Jackie, Dang, Chau, Theodoulou, Maria, Massague, Joan, Norton, Larry, Hudis, Clifford, Traina, Tiffany A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3222913/
https://ncbi.nlm.nih.gov/pubmed/21729667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2011.03.021
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller